Tag archive for ‘Teva Pharmaceutical Industries’
Jewish Business News On Sunday, September 16th, 2018

Teva Wins FDA Nod for Migraine Drug

Teva Pharmaceutical Industries today announced that the US Food and Drug Administration (FDA) has approved AJOVY (fremanezumab) injection for the preventive treatment of migraine in adults. The Israeli company’s More...

Shai Genish On Monday, January 15th, 2018

Israeli authorities Fines Teva $22 Million for Corruption

After a $500 million penalty in the US, Teva Pharmaceutical will be fined NIS75 million in Israel for involvement in a corruption scandal in Eastern Europe, and Mexico. On Monday, the State Prosecutor’s More...

Jewish Business News On Monday, November 6th, 2017

Len Blavatnik examines $3 billion investment in Teva

    Billionaire Len Blavatnik is considering investing $ 3 billion in Teva Pharmaceutical Industries, The Marker has learned. Blavatnik may acquire a significant share of Teva if the company is trading More...

Albert Hecht On Monday, September 11th, 2017

New Teva CEO Kare Schultz grants $20 million in cash, $13.5 million in securities

New Teva CEO Kare Schultz will earn an annual salary of $2 million and a performance-dependent bonus of 140% of the base salary – and up to a maximum of 200%. The Israeli Teva Pharmaceutical Industries has More...

Omri Cohen On Thursday, August 3rd, 2017

Drama in Teva: Cutting 7,000 jobs in 45 countries ; share price plunges

Teva Pharmaceutical Industries announced today that it is cutting 7,000 jobs in 45 countries and will close 15 factories by the end of 2018, following the publication of the financial results of the company More...

Shai Genish On Thursday, December 22nd, 2016

Israeli drugmaker Teva pays $519 million fine in US for foreign bribes

US Justice Department announced Thursday that Israeli Teva Pharmaceutical Industries will pay $519 million fine to settle charges concerning violations of the Foreign Corrupt Practices Act (FCPA). More...

Jewish Business News On Monday, September 19th, 2016

Teva’s Trial Results finds drug could slow Huntington’s disease

Teva Pharmaceutical Industries Ltd. today announced top-line results from an exploratory dose-ranging Phase 2 clinical trial, which could be a major breakthrough in the treatment of Huntigton’s Disease More...

Teva completes acquisition of Allergan’s generics business – Actavis Generics

  Teva Pharmaceutical Industries Ltd. and Allergan plc today announced that Teva has completed its acquisition of Allergan’s generics business – Actavis Generics. Allergan received $33.43 billion More...

Teva buys Allergan distributor Anda for $500 million

  One day after Teva Pharmaceutical Industries closed its deal to buy Allergan’s generics business for $33.43 billion in cash and $5.3 billion in shares, the company purchase Allergan’s 4th largest More...

Teva Sells $15 Billion of Bonds

  Teva Pharmaceutical Industries Ltd. announced today that it sold $15 billion bond offering, Monday to help fund its acquisition of Allergan PLC’s generics division. This makes Teva the latest company More...

Wordpress site Developed by Fixing WordPress Problems